Day One Biopharmaceuticals, Inc. (DAWN)

NASDAQ: DAWN · IEX Real-Time Price · USD
21.45
-0.29 (-1.33%)
At close: Dec 5, 2022 4:00 PM
21.55
+0.10 (0.47%)
After-hours: Dec 5, 2022 7:53 PM EST
-1.33%
Market Cap 1.60B
Revenue (ttm) n/a
Net Income (ttm) -124.01M
Shares Out 71.01M
EPS (ttm) 5.50
PE Ratio 3.90
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 481,321
Open 23
Previous Close 21.74
Day's Range 20.99 - 23.1
52-Week Range 5.44 - 28.35
Beta n/a
Analysts Buy
Price Target 37.74 (+75.9%)
Earnings Date Nov 14, 2022

About DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceutic... [Read more]

Industry Biotechnology
IPO Date May 27, 2021
CEO Jeremy Bender
Employees 102
Stock Exchange NASDAQ
Ticker Symbol DAWN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for DAWN stock is "Buy." The 12-month stock price forecast is 37.74, which is an increase of 75.94% from the latest price.

Price Target
$37.74
(75.94% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

2 weeks ago - GlobeNewsWire

Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

3 weeks ago - GlobeNewsWire

Day One Reports Third Quarter 2022 Financial Results and Corporate Progress

Topline results for full pivotal FIREFLY-1 study population with tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG) are expected in the first quarter of 2023

4 weeks ago - GlobeNewsWire

Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development...

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

1 month ago - GlobeNewsWire

Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage b...

2 months ago - Business Wire

Day One Appoints Garry Nicholson as Chairman of the Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...

2 months ago - GlobeNewsWire

Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in...

4 months ago - GlobeNewsWire

Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

4 months ago - GlobeNewsWire

Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 84.6% in Day One Biopharmaceuticals, Inc. (DAWN). While the effectiveness of this highly sought-after metric is q...

4 months ago - Zacks Investment Research

Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' barga...

Other symbols: KZRLYELMRTXRPTX
5 months ago - Zacks Investment Research

Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additi...

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing tar...

5 months ago - GlobeNewsWire

Here's How Day One Biopharmaceuticals Stock Could Keep Climbing

A giant run-up on Monday could be the beginning of a much larger bull run.

5 months ago - The Motley Fool

Day One Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing tar...

5 months ago - GlobeNewsWire

DAWN Stock Is in the Spotlight as Day One Announces Common Stock Offering

Day One Biopharmaceuticals (DAWN) stock is in the news Tuesday as a common stock offering has the company's shares moving. The post DAWN Stock Is in the Spotlight as Day One Announces Common Stock Offer...

5 months ago - InvestorPlace

Day One Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing tar...

5 months ago - GlobeNewsWire

Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?

Today's announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. The post Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?

5 months ago - InvestorPlace

Why Day One Biopharma Shares Are Surging Today

Day One Biopharmaceuticals (NASDAQ: DAWN) shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib (DAY101) in relapsed or progressive pedia...

5 months ago - Benzinga

Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Lo...

Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib

5 months ago - GlobeNewsWire

Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RA...

Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic effects of the two candidates among adolescents and adults Phase 1b/2 combina...

6 months ago - GlobeNewsWire

Day One Reports First Quarter 2022 Financial Results and Provides Business Update

Initial data from pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG) expected in June 2022

6 months ago - GlobeNewsWire

Day One to Present at the 21st Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...

7 months ago - GlobeNewsWire

Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress

Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022

8 months ago - GlobeNewsWire

Day One to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

9 months ago - GlobeNewsWire

Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

1 year ago - GlobeNewsWire

Day One Reports Third Quarter 2021 Financial Results and Corporate Progress

Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022

1 year ago - GlobeNewsWire